Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 1;77(1):41-45.
doi: 10.1097/QAI.0000000000001561.

Brief Report: PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships

Maria Pyra  1 , Jessica E Haberer  2   3 , Renee Heffron  1 , Lara Kidoguchi  1 , Elizabeth R Brown  4   5 , Elizabeth A Bukusi  1   6   7 , Stephen Asiimwe  8 , Connie Celum  1   9 , Elly Katabira  10 , Nelly R Mugo  1   7 , Jared M Baeten  1   9 ; Partners Demonstration Project Team
Affiliations

Brief Report: PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships

Maria Pyra et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Pre-exposure prophylaxis (PrEP) is efficacious for African women at risk for HIV, but data on adherence outside clinical trials are sparse. We describe the persistence and execution of PrEP use among women participating in a large open-label PrEP demonstration project, particularly during periods of HIV risk.

Setting and methods: Three hundred ten HIV-uninfected women in HIV serodiscordant couples in Kenya and Uganda were offered and accepted PrEP. Electronic monitoring caps were used to measure daily PrEP adherence. Time on PrEP while at risk for HIV (when the HIV-infected partner was on antiretroviral therapy <6 months) and weekly adherence while on PrEP were calculated and compared among older and younger (<25 years old) women.

Results: As defined above, women were at risk for HIV for an average of 361 days; 54% took PrEP during their entire risk period and 24% stopped but restarted PrEP during their risk period. While on PrEP, women took ≥6 doses/wk for 78% of weeks [67% of weeks for women aged <25 years, 80% of weeks for women aged ≥25 years (P < 0.001)], and ≥4 doses for 88% of weeks [80% for those <25, 90% for those ≥25, (P < 0.001)]. Compared with historical, risk-matched controls, HIV incidence was reduced 93% (95% confidence interval: 77% to 98%) for all women and 91% (95% confidence interval: 29% to 99%) among women aged <25 years.

Conclusion: Women, including young women, in HIV-serodiscordant couples took PrEP successfully over sustained periods of risk. Although young women had lower adherence than older women, they achieved strong protection, which suggests that women can align PrEP use to periods of risk and imperfect adherence can still provide substantial benefit.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Weekly Doses While on PrEP Among All Women (A) and Women <25 (B)
See this image and copyright information in PMC

References

    1. Global AIDS Update 2016. Geneva, Switzerland: UNAIDS; [Accessed November 9, 2016]. http://www.who.int/hiv/pub/arv/global-AIDS-update-2016_en.pdf?ua=1.
    1. Karim SSA. [Accessed May 4, 2016];The potential and challenges of ARV-based HIV prevention: An overview. 2014 Jul; http://slideplayer.com/slide/5909872/
    1. Cottrell ML, Yang KH, Prince HMA, et al. A Translational Pharmacology Approach to Predicting HIV Pre-Exposure Prophylaxis Outcomes in Men and Women Using Tenofovir Disoproxil Fumarate±Emtricitabine. J Infect Dis. 2016 Feb; doi: 10.1093/infdis/jiw077. - DOI - PMC - PubMed
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 2015;372(6):509–518. doi: 10.1056/NEJMoa1402269. - DOI - PMC - PubMed
    1. Van Damme L, Corneli A, Ahmed K, et al. Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med. 2012;367(5):411–422. doi: 10.1056/NEJMoa1202614. - DOI - PMC - PubMed

Publication types

Substances